论文部分内容阅读
目的:观察吉西他滨联合多西紫杉醇新辅助化疗方案对晚期非小细胞肺癌(NSCLC)的近期临床疗效及胃肠反应耐受性.方法:156例符合入选标准晚期NSCLC患者随机分为GT组70例,NP组86例,术前接受新辅助化疗(GT组接受吉西他滨联合多西紫杉醇方案,NP组接受长春瑞滨联合顺铂方案),比较两组的临床疗效及胃肠道反应.结果:总有效率GT组47.02,NP组52.37,两组比较无显著性差异(P>0.05);胃肠道反应发生率GT组25.71,NP组79.70,两组比较有显著性差异(P 0.05);Incidence of gastrointestinal reaction was 25.71 in GT group and incidence of gastrointestinal reaction was 79.70 in NP group. there was significant difference between two groups(P<0.05). Conclusion the total efficiency of short-term effect between Gemcitabine plus Docetaxel neoadjuvant chemotherapy and platinum-based is similar. Gastrointestinal reaction is lighter in GT than in NP.Gemcitabine + docetaxel can be used as a preoperative neoadjuvant chemotherapy options.